##### 



Exhibit 99.1

NEWS RELEASE

UROPLASTY, INC. REPORTS THIRD QUARTER FINANCIAL RESULTS
ENDING DECEMBER 31, 2003

Thursday, February 12, 2004

MINNEAPOLIS, MN
Uroplasty, Inc. (OTC: UPST - news) reports its worldwide
financial results for the third quarter ended December 31, 2003.

Net Sales: In the third quarter ended December 31, 2003, net sales of all
products were $1,447,671, representing a $182,929 or 14% increase when compared
to net sales of $1,264,742 for the third quarter ended December 31, 2002.
During the nine months ended December 31, 2003, net sales of all products were
$3,982,333, representing a $119,617 or 3% increase when compared to net sales
of $3,862,716 during the nine months ended December 31, 2002. The sales
increase is the result of favorable fluctuations in foreign currency exchange
rates between the U.S. Dollar (the functional reporting currency) and the Euro
and the British Pound (currencies of the Companys subsidiaries). Excluding the
fluctuations in foreign currency exchange rates, there was a sales decrease of
approximately 1% for the three months ended December 31, 2003 and approximately
11% for the nine months ended. Management believes the decrease in sales is
related to increased competition and healthcare reform in many European
countries with procedures being limited or rationed through reimbursement
systems designed to decrease overall costs to the various national healthcare
systems. Management believes sales will increase going forward with targeted
marketing programs. The Macroplastique product line accounts for 84% to 87% of
total net sales during the periods presented.

Gross Profit: Gross profit was $1,026,484 and $934,727 for the quarter ended
December 31, 2003 and 2002, respectively, or 71% and 74% of net sales. Gross
profit was $2,881,373 and $2,757,698 for the nine months ended December 31,
2003 and 2002, respectively, or 72% and 71% of net sales. Gross profit in any
one period is highly variable depending on unit sales and utilization of
manufacturing capacity. Historically, the gross margin percentage has moved
between approximately 70-80% of net sales.

General and Administrative Expense: General and administrative (G&A) expenses
increased from $312,003 during the third quarter of fiscal 2003 to $510,218
during the third quarter of fiscal 2004 and increased from $884,131 during the
nine months ended December 31, 2002 to $1,432,263 during the nine months ended
December 31, 2003. Increased foreign retirement costs, consulting, legal, and
shareholder expenses, combined with general price increases and fluctuations in
foreign currency exchange rates caused the increase in G&A expenses. The
consulting fees and shareholder expenses relate to the consulting agreements
with the Executive Advisory Group (EAG) to perform services for and on behalf
of the Company and the consulting agreement with C.C.R.I. Corporation to
provide investor relations and development services. The two agreements
accounted for $169,883 and $402,290, respectively, of the increased expense for
the three and nine months ended December 31, 2003.

Research and Development Expense: Research and development (R&D) expenses
decreased $66,889, or 12%, from $538,295 during the third quarter of fiscal
2003 to $471,406 during the third quarter of fiscal 2004 and decreased 14% from
$1,539,503 during the nine months ended December 31, 2002 to $1,330,169 during
the nine months ended December 31, 2003. The decrease in R&D expense resulted
from a decrease in clinical costs due to the February 2003 completion of the
patient enrollment phase in the Companys multi-center IDE clinical trial.

Selling and Marketing Expenses: Selling and marketing (S&M) costs increased
101% from $251,051 during the third quarter of fiscal 2003 to $503,931 during
the third quarter of fiscal 2004 and increased 66% from $764,878 during the
nine months ended December 31, 2002 to $1,268,735 during the nine months ended
December 31, 2003. The increase resulted from recruitment fees, staffing, and dismissal
payments,





---



##### 



travel costs and costs relating to trade-shows, conventions and
congresses, marketing materials, general price increases, and fluctuations in
foreign currency exchange rates. In October and December, changes were made in
sales management resulting in termination expenses and payments in the third
quarter of fiscal 2004 of $105,000.

Other Income (Expense): Other income (expense) includes interest income,
interest expense, foreign currency exchange gains and losses, settlement income
and other non-operating costs when incurred. The Companys financial results
are subject to material fluctuations based on changes in currency exchange
rates. Other income was $13,121 and $152,701 for the third quarter ended
December 31, 2003 and 2002, respectively, and $12,419 and $750,131 for the nine
months ended December 31, 2003 and 2002, respectively. The majority of the
differences between periods were due to foreign currency exchange gains and
losses and the settlement proceeds from the litigation. Exchange gains and
losses are recognized primarily as a result of fluctuations in currency rates
between the U.S. Dollar (the functional reporting currency) and the Euro and
British Pound (currencies of the Companys subsidiaries), as well as their
effect on the dollar denominated intercompany obligations between the Company
and its foreign subsidiaries. At December 31, 2003 and 2002, the Company had
$0.3 million and $2.5 million dollar denominated intercompany debt at its
foreign Dutch subsidiary. These intercompany balances are revolving in nature
and are not deemed to be long-term balances. The Company recognized foreign
currency gains of $11,697 and $146,024 for the third quarter ended December 31,
2003 and 2002, respectively, and $5,126 and $553,357 for the nine months ended
December 31, 2003 and 2002, respectively. The currency gains are primarily the
result of a weakened U.S. Dollar compared to the Euro. In January 2003, the
Company recapitalized one of the Dutch subsidiaries with an investment of 1.5
million Euros ($1.6 million). The Company used proceeds from the investment to
reduce the dollar denominated intercompany debt at the Dutch subsidiary,
resulting in an adjusted balance at December 31, 2002 of $0.9 million of
intercompany debt at the Dutch subsidiary subject for foreign currency
transaction accounting. This resulted in less volatility for changes in
currency exchange rates in the Companys statement of operations.

Income Tax Expense: During the quarter ended December 31, 2003, the Companys
Dutch subsidiaries recorded income tax expense of $97,375 as they have fully
utilized their net operating loss carryforwards. During the nine-months ended
December 31, 2003, the Companys Dutch subsidiaries recorded income tax expense
of $249,789. As of December 31, 2003 $38,808 income tax has been paid, the
remaining part has been accrued and therefore included under current
liabilities. The U.S. net operating loss carryforwards cannot be used to offset
taxable income in foreign jurisdictions. Management expects continued profits
for its Dutch subsidiaries and therefore continued income tax expenses. The
Dutch income tax rate is 29% for euro 22,689 of profit and 34.5% for the amount
above euro 22,689

Uroplasty is a medical device company that develops, manufactures and markets a
family of injectable implant products used for soft-tissue augmentation for
specific indications in urology, urogynecology, colon and rectal,
otolaryngology and plastic surgery markets. The Companys products offer
physicians and their patients a minimally invasive treatment option for urinary
incontinence, vesicoureteral reflux, fecal incontinence, vocal cord
rehabilitation and dermal augmentation. Uroplastys products are CE marked for
these indications and sold in markets outside the United States.

Summary of Operations:

|                                           |         |   |                    |           |                   |  |           |           |          |  |            |           |  |  |           |           | 
|------------------------------------------ | ------- | - | ------------------ | --------- | ----------------- |  | --------- | --------- | -------- |  | ---------- | --------- |  |  | --------- | --------- | 
|                                           |         |   | Three Months Ended |           | Nine Months Ended
|                                           |         |   |                    |           |                  
|                                           |         |   | 12/31/03           |           | 12/31/02          |  | 12/31/03  |           | 12/31/02
|                                           |         |   |                    |           |                   |  |           |           |         
|Net sales                                  |         | $ | 1,447,671          |           |                   |  | 1,264,742 |           |          |  | 3,982,333  |           |  |  | 3,862,716 |          
|Operating loss                             |         |   | (459,071           | )         |                   |  | (166,622  | )         |          |  | (1,149,794 | )         |  |  | (430,814  | )        
|Net income (loss)                          |         | $ | (543,325           | )         |                   |  | (13,921   | )         |          |  | (1,387,164 | )         |  |  | 319,317   |          
|Basic income (loss) per common share       |         | $ | (0.12              | )         |                   |  | (0.00     | )         |          |  | (0.31      | )         |  |  | 0.09      |          
|Diluted income (loss) per common share     |         | $ | (0.12              | )         |                   |  | (0.00     | )         |          |  | (0.31      | )         |  |  | 0.09      |          
|Weighted average common shares
outstanding |         |   |                    |           |                   |  |           |           |          |  |            |           |  |  |           |          
|                                           | Basic   |   |                    | 4,530,657 |                   |  |           | 4,467,547 |          |  |            | 4,500,677 |  |  |           | 3,564,155 | 
|                                           | Diluted |   |                    | 4,530,657 |                   |  |           | 4,467,547 |          |  |            | 4,500,677 |  |  |           | 3,587,996 | 





---



##### 



Selected Consolidated Balance Sheet Data

|                                     |                                                    |  |                                     |           |                   |         |                |           |  |         | 
|------------------------------------ | -------------------------------------------------- |  | ----------------------------------- | --------- | ----------------- | ------- | -------------- | --------- |  | ------- | 
|                                     |                                                    |  |                                     |           | December 31, 2003 |         | March 31, 2003
|                                     |                                                    |  |                                     |           |                   |         |               
|Assets                               |                                                    |  |                                     |           |                   |         |                |          
|                                     | Current assets                                     |  | $                                   | 4,431,827 |                   |         |                | 4,988,843 | 
|                                     | Property, plant, and equipment, net                |  |                                     | 1,075,488 |                   |         |                | 833,234   | 
|                                     | Intangible assets, net of accumulated
amortization |  |                                     | 49,607    |                   |         |                | 48,214    | 
|                                     |                                                    |  |                                     |           |                   |         |                |          
|                                     | Total assets                                       |  | $                                   | 5,556,922 |                   |         |                | 5,870,291 | 
|                                     |                                                    |  |                                     |           |                   |         |                |          
|Liabilities and Shareholders Equity |                                                    |  |                                     |           |                   |         |                |          
|                                     | Current liabilities:                               |  |                                     |           |                   |         |                |           | 
|                                     |                                                    |  | Accounts payable                    |           | $                 | 131,813 |                |           |  | 199,673 | 
|                                     |                                                    |  | Income tax payable                  |           |                   | 226,365 |                |           |  |        | 
|                                     |                                                    |  | Accrued liabilities                 |           |                   | 317,986 |                |           |  | 349,937 | 
|                                     |                                                    |  | Current
maturities  long-term debt |           |                   | 43,350  |                |           |  | 37,502  | 
|                                     |                                                    |  |                                     |           |                   |         |                |          
|                                     | Total current liabilities                          |  |                                     | 719,514   |                   |         |                | 587,112   | 
|                                     | Long-term debt  less current
maturities           |  |                                     | 502,454   |                   |         |                | 462,787   | 
|                                     |                                                    |  |                                     |           |                   |         |                |          
|                                     | Total liabilities                                  |  |                                     | 1,221,968 |                   |         |                | 1,049,899 | 
|                                     | Shareholders equity                               |  |                                     | 4,334,954 |                   |         |                | 4,820,392 | 
|                                     |                                                    |  |                                     |           |                   |         |                |          
|                                     | Total liabilities and
shareholders equity         |  | $                                   | 5,556,922 |                   |         |                | 5,870,291 | 
|                                     |                                                    |  |                                     |           |                   |         |                |          

The Private Securities Litigation Reform Act of 1995 provides a safe harbor
for certain forward-looking statements. This press release contains
forward-looking statements, including our internal projections of anticipated
fiscal 2004 operating results, which reflect our views regarding future events
and financial performance. These forward-looking statements are subject to
certain risks and uncertainties, including those identified below, which could
cause actual results to differ materially from historical results or those
anticipated. The words aim, believe, expect, anticipate, intend,
estimate and other expressions which indicate future events and trends
identify forward-looking statements. Actual future results and trends may
differ materially from historical results or those anticipated depending upon a
variety of factors, including, but not limited to: the effect of government
regulation, including when and if we receive approval for marketing of our
products in the United States; the impact of international currency
fluctuations on our cash flows and operating results; the impact of
technological innovation and competition; acceptance of our products by
physicians and patients, our reliance on a single product for most of our
current sales; our intellectual property and the ability to prevent
competitors from infringing our rights; the ability to receive third party
reimbursement for our products; the results of our current human clinical
trial; our continued losses and the possible need to raise additional
capital in the future; our ability to manage our international operations;
our ability to hire and retain key technical and sales personnel; our
dependence on key suppliers; future changes in applicable accounting rules;
and volatility in our stock price.

Uroplasty, Inc. stock is traded on the OTC Bulletin Board system under the
symbol UPST.OB.

FOR FURTHER INFORMATION: visit Uroplastys web page at www.uroplasty.com or
contact Mr. Holman.





---



##### 



UROPLASTY, INC.
Daniel G. Holman, President / CEO
2718 Summer Street NE, Minneapolis, MN 55413-2820
Tel: 612-378-1180
Fax: 612-378-2027
E-mail: danielh@uroplasty.com